Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Oral Anticoagulation Therapy Withdrawal After Successful Cardiac Ablation in Patients With Atrial Fibrillation and Associated High Risk Factors for Embolic Events (OAT Pilot Study)

NCT01959425 is registered in ClinicalTrials.gov with Biosense Webster, Inc. as lead sponsor.

NCT NCT01959425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01959425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Oral Anticoagulation Therapy Withdrawal After Successful Cardiac Ablation in Patients With Atrial Fibrillation and Associated High Risk Factors for Embolic Events (OAT Pilot Study)
Lead sponsor
Biosense Webster, Inc.
Phase
Phase 4
Overall status
Terminated
Start date
April 17, 2013
Completion date
October 7, 2019
Enrollment
80 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal atrial fibrillation